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ABSTRACT 
 
The government of Namibia established a comprehensive HIV/AIDS treatment and care 
programme in 2002. This programme provides anti-retroviral treatment to all eligible HIV 
patients in the public health sector. The antiretroviral treatment programme in Keetmanshoop 
started in October 2003. Adherence to treatment regimes in HIV care is a key factor in 
determining clinical outcomes and is associated with improved survival among HIV and 
AIDS patients. Sustained high levels of adherence (95% or more) are essential for the success 
of highly active antiretroviral therapy (HAART). Maintaining high adherence levels is 
therefore a major concern in HIV/AIDS treatment programmes. This study investigated 
adherence to HAART among patients in the Keetmanshoop antiretroviral therapy (ART) 
clinic and the factors that affect adherence. 
Aim of the research 
The aim of the research was to describe adherence to HAART and factors influencing 
adherence among patients in Keetmanshoop ART clinic, Namibia.  
Objectives 
1. To describe levels of adherence to HAART amongst clients at Keetmanshoop ART clinic. 
2. To assess the changes in CD4 count and body weight of clients on HAART over a 12 
month period. 
3. To assess factors associated with adherence to HAART. 
4. To analyse associations between CD4 count and adherence. 
5. To analyse associations between changes in body weight and adherence.  
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Methodology 
A quantitative descriptive cross-sectional survey was used. The study population included all 
clients 18 years and above, who were on HAART for one year or more at the Keetmanshoop 
clinic. One hundred and six clients participated in the study. Data was collected through an 
interview with the participants and a review of clinical records. 
 
Results  
Most respondents had good adherence levels; with 86.1% reporting optimal adherence levels. 
The respondents also showed an increase of median CD4 counts from 126 cells/µl at baseline 
to 304 cells/µl at 12 months and an increase in body weight from an average of 50kg at 
baseline to an average of 57kg at 12 months. Adherence levels were found to have an impact 
on CD4 cell counts and on body weight, with respondents who had sub-optimal adherence 
experiencing a drop in median CD4 cell counts and median body weight by 12 months. 
Living far from the clinic (>10km) was found to be the only factor significantly associated 
with sub-optimal adherence.  
 
Conclusion  
The study showed a positive correlation between adherence levels and CD4 cell counts and 
body weight gain. In the absence of viral load, CD4 cell count testing can be used as a 
measure of adherence. Though most respondents appear to be adhering well to HAART, a 
sub-optimal adherence rate of >10% is a concern for the Keetmanshoop ART programme and 
will need to be addressed. There is a need for further research to determine the level of 
default or attrition from HAART in the programme.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 GLOBAL HIV/AIDS EPIDEMIC  
1.1.1 GLOBAL STATUS OF THE HIV EPIDEMIC 
Acquired immunodeficiency syndrome (AIDS) was first recognised in 1981 and the Human 
immunodeficiency virus (HIV) identified and confirmed as a necessary and sufficient cause 
of AIDS in 1983 (Hoffman, Rockstroh & Kamps, 2005). Since then the HIV epidemic has 
increased exponentially and spread widely to become a global pandemic. UNAIDS reported 
that there were 32.9 million people living with HIV/AIDS worldwide, 2.2 million new HIV 
infections and 2 million HIV-related deaths in 2007 (UNAIDS, 2008). Sub-Saharan Africa, 
with only a tenth of the world’s population, had the highest burden of HIV/AIDS. This region 
accounted for 67% of all people living with HIV/AIDS, 60% of all new HIV infections and 
75% of all HIV-related deaths worldwide (UNAIDS, 2008).   
 
1.1.2 HEALTH AND SOCIAL IMPACT OF HIV 
HIV/AIDS has not only been a health issue but has had substantial social, economic and 
developmental impacts (Dixon, McDonald & Roberts, 2002). The epidemic has mainly 
affected people during their most productive years, in early and mid-adulthood. Impact on 
macro-economy has included loss of skilled workers, reduced productivity due to ill health 
and increased training cost for new workers when skilled workers die (Dixon et al, 2002; 
Economic commission for Africa, Undated). Early HIV/AIDS-associated mortality has led to 
a drop of life expectancy to less than 50 years in most countries in sub-Saharan Africa. Life 
expectancy in Zimbabwe, for example, has dropped from 69 years to 40 years (Economic 
Commission for Africa, Undated). In Namibia the  life expectancy had dropped from 59 and 
63 years for men and women respectively in 1991 to 48 and 50 years in 2001 (Ministry of 
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Health and Social Services [MOHSS], 2008a). HIV/AIDS has also been postulated to be a 
national security threat as it takes a toll on the police and armed forces, affecting maintenance 
of law, order and security (Feldbaum, Lee & Patel, 2006). 
 
At the family level, poverty increases when the breadwinner succumbs to HIV and AIDS, 
leading to reduced household income and scarce financial resources being used to pay for 
medical care (Global Action for Children, 2009). As parents die of AIDS, children are 
orphaned and are left under care of elderly grandparents, other over-burdened relatives or 
fending for themselves (Economic Commission for Africa, Undated). UNAIDS estimated 
that there were close to 12 million children orphaned as a result of HIV and AIDS in sub-
Saharan Africa in 2007 (UNAIDS, 2008). In southern African countries, at least half of the 
children orphaned nationally are as a result of HIV/AIDS (Pennington, Kanabus & Pembrey, 
2009).  
 
Children affected or orphaned by HIV/AIDS may suffer socially, psychologically and 
economically. They are at risk of separation from siblings and familiar environments, 
exploitation by care-givers or other adults, loss of their rightful inheritance, stigma and 
discrimination and lack of educational opportunities (Global Action for Children, 2009). 
Without social and economic support, these orphaned children may not develop their full 
potential or the appropriate social and life skills needed for a productive adult life (UNAIDS, 
2009; Global Action for Children, 2009). This could have long-term effects and translate into 
low productivity a generation later (Economic Commission for Africa, Undated). 
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1.1.3 IMPACT OF ANTIRETROVIRAL TREATMENT  
Treatment with highly active antiretroviral therapy (HAART) significantly reduces the HI-
virus in a person and slows down the progression of HIV disease to AIDS (Hoffman et al, 
2005). HAART has transformed HIV/AIDS from a fatal disease to a manageable chronic 
disease and given hope to millions of people living with HIV/AIDS (O’Reilly, 2005; 
UNAIDS, 2008). HAART has been found to reduce HIV/AIDS-related mortality, morbidity 
and hospitalisations.  A study on mortality in sub-Saharan Africa found that the excess 
mortality of persons with HIV/AIDS is reduced by HAART and mortality approaches that of 
the general population in the second year on treatment (Brinkof, Boulle, Weigel, Messou, 
Mathers, Orrell et al, 2009).  
 
By reducing HIV-related morbidity, HAART lessens the social and economic impact of the 
HIV epidemic, by improving productivity and reducing expenditure on treatment of 
opportunistic infections and hospitalisations. This is exemplified by a study in a private 
company in Abidjan in the period 1998 to 2000 (Ehoile, Bissagnene, Gaumon, Mambo, 
Guiza, Kakou & Kadio, 2002). This study found that workplace HIV strategies which 
included prevention activities, voluntary counselling and testing (VCT), provision of care and 
antiretroviral treatment, were associated with a three-fold reduction in the cost of caring for 
HIV-positive employees and a ten-fold decrease in absenteeism.  
 
HAART has been shown to have an impact on the prevention of new HIV infections 
(Montaner, Hogg, Wood, Kerr, Tyndall, Levy & Harrigan, 2006). By suppressing viral 
replication, HAART reduces HIV-1-RNA concentrations in plasma, semen, vaginal 
secretions and breast milk. Studies in HIV sero-discordant couples and in mother-to-child 
transmission settings have shown that the risk of HIV transmission is dramatically reduced 
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when HIV-1-RNA levels are <1000 copies/ml (Montaner et al).  Availability of HAART also 
had positive influences on VCT uptake, with more people willing to test for HIV now that 
treatment is available. In Haiti, use of VCT increased by 300% within 2 years of starting an 
antiretroviral treatment programme (Koenig, Leandre, & Farmer, 2004). Most people tested 
negative and this provided health workers opportunities for promoting preventive behaviours.  
 
1.1.4 ACCESS TO ANTIRETROVIRAL THERAPY 
Antiretroviral therapy was previously very expensive and out of reach for millions of people 
living with HIV/AIDS in the developing countries. There have been intense international 
efforts to make the treatment affordable and available to as many people as need it, especially 
in the developing countries (Cameron & Gupta, 2002). As a result of these efforts, there were 
2.99 million people on HAART in medium and low income countries by the end of 2007 
(Brinkof et al, 2009). This represented 31% of the estimated 9.6 million people in need of 
treatment in these countries. In sub-Saharan Africa the people on HAART increased from 
1.38 million in 2006 to 2.12 million in 2007 (Brinkof et al, 2009). With improved access to 
HIV treatment, the focus has shifted to maintaining optimal adherence to HAART and 
retaining patients in treatment programmes in the long-term.  
 
1.1.5 ADHERENCE TO ANTIRETROVIRAL THERAPY 
Adherence can be defined as the extent to which patients take their medication as prescribed 
(Osterberg & Blaschke, 2005). Adherence is an ongoing challenge in the management of 
many chronic diseases. The consequences of poor adherence are poor health outcomes and an 
increase in the disease burden as well as increased health care costs (WHO, 2001). Poor 
adherence has been found to be the most important reason why HAART regimens fail 
(Boyle, 2000). Maintaining very high levels of adherence (taking more than 95% of the 
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prescribed antiretroviral medication) is essential to suppress HIV replication (Gill, Hamer, 
Simon, Thea & Sabin, 2005). Suppression of viral replication is associated with improved 
biological and clinical outcomes. Adherence levels that are below 95% (sub-optimal) have 
been found to lead to rebound viral replication with the possibility of the emergence of 
resistant HIV variants. This could cause treatment failure and progression of disease to AIDS 
(Bangsberg, Perry, Charlebois, Clark, Robertson, Zolopa et al, 2001; McNicholl, 2008).  
 
1.1.6 HEALTH AND SOCIOECONOMIC CONSEQUENCES OF POOR ADHERENCE 
TO HAART  
Poor adherence to HAART could have serious consequences for both the individual and the 
wider community. At the community level, there is a risk of an increased prevalence of 
resistant HIV strains and transmission of the resistant HIV strains in the general population, 
especially in primary infections (Poppa, Davidson, Deutsch, Godfrey, Fisher, Head et al, 
2003). At individual level, poor adherence could result in viral resistance and treatment 
failure which could lead to progression of disease with re-emergence of opportunistic 
infections (Poppa et al, 2003). Treatment failure would necessitate use of 2nd line regimens 
which are more complex, more expensive and associated with more toxicities. Treating 
opportunistic infections and the use of 2nd line regimens increases health care costs and 
reverses the earlier economic benefits of HAART. Poor adherence has also been shown to 
increase the risk of mortality, especially at very low CD4 cell counts (Abaasa, Todd, Ekoru, 
Kalyango, Levin, Odeke et al, 2008).  
 
It is therefore imperative that HIV treatment programmes aim for sustained high levels of 
adherence to HAART to prevent development of drug-resistant HIV strains. Knowing 
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adherence behaviour and factors that influence adherence would help treatment programmes 
develop strategies that assist persons on treatment maintain optimum adherence levels. 
 
1.2 STUDY SETTING  
1.2.1 COUNTRY BACKGROUND – NAMIBIA  
Namibia has a high burden of HIV/AIDS. The national HIV prevalence in the general 
population in Namibia is estimated at 19.6% (The President’s Emergency Plan for AIDS 
Relief [PEPFAR], 2008). According to the 2001 census, Namibia has a population of 
1,830,330 million people (MOHSS, 2008a). It is sparsely populated with a population density 
of 2.1 /km2.  Forty-three percent (43%) of the population is under 15 years; and 33% live in 
urban areas.  
 
The first identified case of HIV/AIDS in Namibia was in 1986 (MOHSS, 2008b). Since then 
HIV/AIDS has grown to reach epidemic levels in the general population. The first HIV 
antenatal surveillance in 1992 showed a HIV prevalence of 4.2% among pregnant women 
attending antenatal care (ANC). This prevalence increased and peaked in 2002 at 22% and 
has been dropping since. In 2008, the national HIV prevalence among pregnant women 
attending ANC was 17.8 % (MOHSS, 2008b). UNAIDS estimates that there were 200,000 
people living with HIV/AIDS in Namibia in 2007 (UNAIDS, 2008). AIDS accounts for 50% 
of deaths among persons aged 15-49 year while 75% of all hospitalizations in public hospitals 
are HIV-related (UNAIDS , 2008).  
 
The government of Namibia has made the fight against HIV/AIDS a top priority. In 2003 the 
government introduced antiretroviral treatment as a component of Comprehensive HIV/AIDS 
Care. This programme provides anti-retroviral treatment to all eligible HIV positive patients, 
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at no cost to the patient, in the public health sector (MOHSS, 2007). The programme started 
at six pilot hospitals and had expanded to all 34 hospitals in the country by year 2006. By end 
of 2006, 30% of all patients in need of treatment for HIV had started receiving HAART 
(MOHSS, 2007). Sixteen percent of the patients on HAART are children. Women accounted 
for 64% of all adult patients on HAART nationwide in the public sector (MOHSS, 2007).  
 
Monitoring of patients is done through 6-monthly CD4 cell count checks. In 2007 the 
Ministry introduced viral load testing as a monitoring tool and is done at 6 months after 
starting HAART. In a review of viral load results, 66% of the patients on HAART in the 
public sector were found to have viral loads in the range of 40-1000 copies/ml (MOHSS, 
2009). The Technical Advisory Committee has recommended that patients who have viral 
loads <1000 copies/ml should be considered to be adequately suppressed (MOHSS, 2009).  
 
1.2.2 DISTRICT BACKGROUND – KEETMANSHOOP  
Keetmanshoop district is in the southern region of Namibia. Keetmanshoop district is 
sparsely populated with a total population of 36,427 and a population density of 0.69 per km2 
(Keetmanshoop District Coordinating Committee [DCC], 2008). Keetmanshoop district is 
served by one hospital, two health centres and five clinics. There is also an outreach mobile 
unit that provides health services to areas that are far from the clinics. Transport is a 
challenge in the district due to the vastness of the district and lack of public transport. Only a 
small percentage of the population have access to private vehicles. Most people use donkey 
carts for transportation. This affects access to health services and has been a challenge in the 
ART programme in reaching those HIV positive citizens in need of HAART who live far 
from the health services (Keetmanshoop DCC, 2008).  
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HIV is one of the major public health challenges in the district (Keetmanshoop DCC, 2008). 
The 2008 Antenatal HIV surveillance showed a HIV prevalence of 12.7% among antenatal 
attendees in the district (MOHSS, 2008b).  The ART programme in Keetmanshoop district 
started in October 2003. By the end of 2007, 1622 adults and 103 children were registered for 
chronic HIV care on the programme. Of these, 675 adults and 73 children receive HAART 
(Keetmanshoop DCC, 2008). Adherence to HAART is the cornerstone of successful ART 
programme. Clients on HAART are encouraged and supported to adhere to treatment at every 
opportunity. The Keetmanshoop programme has community counsellors involved in 
counselling clients on positive living and adherence to treatment.  All health workers are also 
encouraged to emphasise adherence and commitment to treatment with every contact with the 
client. Despite these efforts, the ART defaulter rate by end of 2007 was about 5.9% 
(Keetmanshoop DCC, 2008).  
 
1.3 PROBLEM STATEMENT 
Since the initiation of the Keetmanshoop ART programme, no formal study has been 
conducted to assess clients’ adherence to HAART. In the monthly Keetmanshoop ART 
committee meetings, it is reported that most clients on treatment are satisfied with the care 
received, and are highly motivated to adhere to treatment. However, it is essential to research 
and describe adherence behaviour of patients and the factors that affect this behaviour as this 
information could be used to improve adherence counselling and develop strategies to 
maintain high adherence levels.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 INTRODUCTION  
The current study will research adherence behaviour in Keetmanshoop ART clinic and 
factors associated with adherence and compare the findings with studies done in other 
settings in Africa. This chapter reviews the literature available on adherence measures, 
factors influencing adherence and findings from other studies done in Africa.  
 
2.2 MEASURING ADHERENCE 
Measuring adherence to medication accurately is complicated, even in well-resourced 
countries. The ideal measurements would be directly observing a patient take the medicines 
(directly observed therapy – DOT) or methods that measure the drug levels or its metabolite 
in the blood (Osterberg & Blaschke, 2005). Measuring a biological marker in the blood and 
electronic drug monitoring through medication events monitoring systems (MEMS) are 
indirect measures that are precise. These methods are expensive and out of reach for most 
public health systems in sub-Saharan Africa. Adherence can also be measured by asking 
patients about their pill-taking habits (Osterberg & Blaschke, 2005). Adherence estimates by 
self-report are usually high as patients tend to over-report adherence. A drawback with self-
reporting is that it depends on patient’s belief and interpretation of adherence (Hill, Kendall 
& Fernandez, 2003). A patient may modify their regime or change the timing of doses for 
his/her own convenience and still consider himself/herself adherent. A patient may also take 
breaks from therapy but be adherent the other times and consider himself/herself adherent.  
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Pill counts, pharmacy refill records and keeping of appointments are other objective methods 
that can be used as indirect measures of adherence (Osterberg & Blaschke, 2005; Coates, 
2003). In a study in Mozambique, adherence to appointments was used as a measure of 
treatment adherence (Marazzi, Bartolo, Gialloreti, Germano, Guidotti, Liotta et al, 2006). In a 
study in South Africa where researchers were comparing the accuracy of adherence-based 
monitoring and CD4 cell monitoring to detect current or predict future virologic failure, 
pharmacy refill data was used to measure adherence (Bisson, Gross, Bellamy, Chittams, 
Hislop, Regensberg et al, 2008). The limitation of pill counts is that patients may manipulate 
pill counts by dumping some pills so as to have the correct number. Measuring adherence by 
pharmacy refill records and keeping of appointments presupposes that patients will actually 
take the medications they collect from the pharmacy appropriately. 
 
Adherence can also be measured by determining the physiological or clinical response to 
therapy. Patients on HAART have experienced improvements in quality of life and fewer 
opportunistic infections (Stone, 2002). Patients also report improved appetites (Nakiyemba, 
Aurugai, Kwasa & Oyabba, 2004). In a study by Verweel (2002) and others, HAART had a 
positive influence in growth in children. (Verweel, Rossum, Hartwig, Wolfs, Scherpbier & 
De Groot, 2002). The body mass index increased in children who had a reduction of viral 
load of at least 1.5 log. This increase was more in children with advanced disease and 
malnutrition (Verweel et al, 2002). Another study investigated the cumulative probability of a 
weight gain equal or greater than 10% in patients starting HAART (Teshale, Hanson, Sulivan 
& Wolfe, 2004). Weight gain was highest in patients starting therapy with CD4 cell counts < 
200 and/or BMI < 20. The cumulative probability of a weight gain >/= 10% in these patients 
was 0.15. However the weight gain was found not to correlate with changes in viral load or 
CD4 counts and was therefore not useful as a surrogate marker (Teshale et al, 2004). 
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Virological response is determined by measuring the viral loads while immunological 
response is determined by measuring the CD4 cell counts (Hoffman et al, 2005). The 
measure of treatment success is the ability of HAART to suppress viral replication. This is 
done through monitoring of viral load. Viral load is very sensitive to adherence levels and 
suppression to undetectable levels is dependent on very high levels of adherence. Failure to 
suppress viral load or a viral rebound to detectable levels in a patient who previously had 
viral suppression is usually due to moderate or low adherence levels (Bisson et al, 2008). 
Measurement of adherence by other methods can be correlated by viral load testing. However 
in the presence of resistance, viral loads may remain high despite optimal levels of adherence.  
 
In absence of viral load testing, the WHO recommends using CD4 cell counts in monitoring 
patients on HAART in resource-limited settings. However CD4 cell levels start declining 
after virologic failure (Bisson et al, 2008). CD4 cell counts can also be affected by inter-
current diseases. In the study by Bisson and others (2008), the researchers found that at 6 and 
12 months, pharmacy refill adherence levels predicted virologic failure more accurately than 
CD4 cell count changes. Adherence levels during the first 3 months were also able to predict 
virologic failure at 6 months. The researchers suggest that monitoring adherence levels may 
provide an accurate early warning of virologic failure. It could help identify patients at risk of 
virologic failure. This provides an opportunity to intensify adherence support thus averting 
treatment failure and the cost of changing to 2nd line regimens. 
 
2.3 FACTORS AFFECTING ADHERENCE 
Social and psychological assessment of patients before start of HAART can help identify 
factors that may cause problems with adherence (Duran, 2004). This assessment could allow 
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the clinicians to prioritize support for patients who may seem to have higher levels of social 
risk for poor adherence. However, the ability of clinicians to predict which patients are likely 
to adhere to taking medication has been shown to be limited. In a study reported by Stone 
(2002) clinicians’ predictions about which patients were likely to have adherence >80% were 
incorrect for 41% of their patients. In a Botswana study clinicians had a 68% likelihood of 
correctly estimating their patients’ adherence levels (Weiser, Wolfe, Bangsberg, Thior, 
Gilbert, Makhena et al, 2003). Adherence is not necessarily static but may change in a 
particular patient over times due to different circumstances (Stone, 2002). A patient’s ability 
to adhere to treatment and to maintain optimal adherence is influenced by various factors that 
affect his/her life. These factors may be patient-related, medication-related, or health system-
related. 
 
Patient-related factors 
A patient’s adherence behaviour may be affected by social, economic and psychological 
factors (Kagee, 2004). Forgetfulness, being too busy, a change in daily routine, and travelling 
without medication have been cited as frequent reasons why patients did not adhere to 
treatment (Murphy, Roberts, Martin, Marelich & Hoffman, 2000; Weiser et al, 2003; Mills 
Nachega, Bangsberg, Singh, Rachlis, Wu et al, 2006). Fear of disclosure, alcohol and drug 
abuse, stress, worries in everyday life, depression, feeling angry or hopeless and not wanting 
to be seen taking HAART in public were other reasons cited for poor adherence (Murphy et 
al, 2000; Mills et al, 2006). Some patients may stop their treatment for periods of time when 
they feel healthy (Murphy et al, 2000).  
 
In studies in well-resourced countries only depression, active alcohol abuse, active injection 
drug use and low literacy have been found to consistently predict poor adherence (Stone, 
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2002). Socio-economic status, age, sex or educational level have not been found to be 
significantly associated with adherence to HAART (Nachega, Stein, Lehman, Hlatshwayo, 
Mothopeng, Chaisson & Karstaedt, 2005; Coetzee, Boulle, Hildebrand, Asselman, Cutsem & 
Goemaere, 2004; Stone, 2002; Weiser et al, 2003). Nachega and others (2005) found that fear 
of stigma from the partner was among the main risk factors for poor adherence to HAART in 
Soweto, South Africa. 
 
A patient’s commitment to medication is also influenced by their belief about the illness, 
acceptance of illness and their belief about the effectiveness of the treatment (Kagee, 2004). 
Improvement in health status increases confidence in the medication and motivates a patient 
to continue adhering (Watt, Maman, Earp, Eng, Setel, Golin et al, 2008). A patient’s self-
confidence and self-worth and his/her belief of where the responsibility for recovery lies will 
also affect how adherent they are to therapy (Kagee, 2004). When a patient is more 
knowledgeable about the illness and the treatment they are more likely to adhere.  
 
Knowledge about HIV has been found to be high in Africa. In a South African KAPB study, 
89% of persons knew that HIV causes AIDS and 65% of persons knew that missing HAART 
doses could lead to disease progression (Nachega et al, 2005).  In the 2006-2007 Namibia 
Demographic and Health Survey (NDHS) comprehensive knowledge about HIV causes and 
transmission among young people aged 15-24 years was 65% for women and 62% for men 
(MOHSS, 2008a). In a study in Botswana 98% and 96% of participants knew the modes of 
transmission of HIV and the modes of prevention of transmission respectively (Weiser et al, 
2003). Interventions that increase clients’ knowledge and insight into the illness and 
treatment facilitate adherence. In an experimental study in France, an educational 
intervention was found to have an impact on adherence levels in a group that received an 
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educational intervention (Goujard, Bernard, Sohier, Peyramond, Lancon, Chwalow et al, 
2003). Mean adherence scores in this group was +0.25 and +0.22 while that of a control 
group was -0.19 and -0.05 at 6 and 12 months respectively. After the control group 
underwent the educational intervention, the mean adherence scores were similar in both 
groups at 18 months (Goujard et al, 2003). 
 
Social support has also been found to be a predictor of good treatment adherence (Kagee, 
2004). Encouragement from family, friends and health workers influences a patient 
positively. An ethnographic study conducted in three African countries to explore better 
adherence levels found in Africa has concluded that social support and responsibilities played 
a major part in ensuring patients’ adherence to HAART (Ware, Idoko, Kaaya, Biraro, Wyatt, 
Agbaji et al, 2009). Patients were helped by family members, treatment partners and 
sometimes health workers both socially and financially. These helpers expected good 
adherence and made their expectations known. This created a responsibility to the patient to 
adhere to treatment so that their health would improve. With improved health, the burden of 
caring for the patient is reduced and he/she is able to meet his/her social and family 
obligations (Ware et al, 2009).  
 
Family support and support from neighbours and other community members were also found 
to be major contributors to good adherence in Uganda (Nakiyemba et al, 2004). In Tanzania 
patients received material and emotional support from friends and family which helped with 
adherence (Watt et al, 2008). This study found that the need for patients to stay healthy to 
meet family obligations was an important motivator for adherence. The patients also 
developed strategies that linked pill-taking to their daily routines thus enhancing adherence. 
This was also seen in a study in Belgium where care-givers to paediatric patients on HAART 
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develop their own daily strategies to ensure their children adhere to HAART (Hammami, 
Nostlinger, Hoeree, Lefevre, Jonckheer & Kolsteren, 2004). 
 
Medication-related factors 
High pill burdens, frequency of dosing and dietary restrictions are some of the factors that 
may contribute to poor adherence (Osterberg & Blaschke, 2005). Unpalatable medicines, side 
effects and complex regimens also contributed to poor adherence. Adherence has been shown 
to improve as frequency of dosing is reduced (Osterberg & Blaschke, 2005). In the well-
resourced countries, the experience of side-effects to the medication has been a significant 
predictor of adherence. However, due to the unique nature of HIV and the lifeline 
antiretroviral therapy has provided for HIV-positive patients in Africa, medication-related 
factors have not adversely affected adherence. It has been suggested in literature that people 
in Africa have higher motivation for adherence to HAART and are more accepting of side 
effects because “they see and experience the disastrous effects of untreated HIV/AIDS 
everywhere in their daily lives” (Nachega et al, 2005; Weiser et al, 2003). 
 
In a South African study, medication-related food restrictions and taking 10 or more tablets 
per day were not significantly associated with adherence (Orrell, Bangsberg, Badri & Wood, 
2003). One HAART client in a Ugandan ART programme, while commenting on the high 
pill burden per day, said “I would be prepared to take 100 pills every day if that was what 
was needed, because I know what the alternative is” (UNAIDS, 2003). In Soweto, South 
Africa, Botswana and Mozambique, though patients experienced side effects, only a small 
percentage said this affected their adherence. This was also seen in Uganda where patients 
took their treatment despite the side-effects (Nakiyemba et al, 2004). There have been 
significant improvements in antiretroviral medications, with pills that can be taken twice or 
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once daily and co-formulations incorporating 2 or 3 types of medicine in a single pill (Stone, 
2002). These innovations reduce dosing frequency and the number of tablets per dose. 
Currently most antiretroviral regimens are taken twice daily with 1 to 3 tablets per dose. 
 
Health system-related factors 
A poor relationship with the health care provider and dissatisfaction with the provider can 
lead to poor adherence. Trust in the health care provider and satisfaction with the service 
promotes confidence and compliance of instructions of the health workers (Osterberg & 
Blaschke, 2005); Watt et al, 2008). Other health systems related barriers to adherence include 
cost, distance to facility and availability of medication. In studies in Malawi and Botswana 
where treatment was sourced privately, financial constraints were a major factor in gaps in 
adherence (Van Oosterhout, Bodasing, Kumwenda, Nyirenda, Mallewa, Cleary et al, 2005; 
Weiser et al, 2003). In Cote D’Ivoire, the main barriers to adherence identified were cost of 
treatment and stock-outs of medication in the pharmacy (Ehoile et al, 2007).  The Malawi 
study also reported stock-outs as a barrier to adherence. Cost as a factor affecting adherence 
was also seen in the Senegalese programme where adherence improved in the second year 
after the amount to be paid by the client reduced (Laniece, Ciss, Desclaux, Diop, Mbodj, 
Ndiaye et al, 2003). In a Ugandan study patients related their difficulties in raising money for 
transport to the clinics and sometimes walking to clinics when there were no funds 
(Nakiyemba et al, 2004). 
 
2.4 ADHERENCE IN AFRICAN STUDIES  
Findings from pilot programmes and research-based anti-retroviral programmes showed high 
levels of adherence to HAART in Africa. The clients had a lot of support from the 
programmes. In a Senegalese pilot programme, 88% of clients had good adherence levels 
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(Laurent, DiaKhate, Gueye, Toure, Sow, Faye et al, 2002). At an adult HIV clinic in Soweto, 
South Africa, a survey found 88% of clients having 95% adherence in the previous one 
month (Nachega et al, 2004). In another South African study, the median adherence level was 
93.5%. Of those who had 95% or more adherence, 73.4% had viral loads of <400 at 48 weeks 
on treatment (Orrell et al, 2003). These high levels of adherence have persisted as access to 
antiretroviral therapy increased.  In two health facilities in Gauteng, South Africa, Kigozi 
(2008) found 88.8% of clients having adherence levels of 95% and above. In a meta-analysis 
of studies in Africa and North America, the African studies showed favourable adherence 
levels with a pooled adherence for African studies of 77% compared to the American studies’ 
level of 55% (Mills, Nachega, Buchan, Orbinski, Attaran, Singh et al, 2006).  
 
However, there is a fear that as antiretroviral therapy programmes expand, there could be 
increased problems with adherence and loss to follow up. This was observed in a study in 
Abidjan, Cote D’Ivoire where treatment was offered on a large scale in three public clinics. 
In this study, adherence in three urban clinics was found to be sub-optimal (<90%) in 76% of 
the patients (Eholie, Tanon, Polneau, Ouiminga, Djadji, Kangah-Koffi et al, 2007). Another 
problem is attrition of patients in the antiretroviral treatment programmes. In a meta-analysis 
of studies from 13 African countries, mean retention rates of patients in treatment 
programmes was found to be 79.1%, 75% and 61.6% at 6, 12 and 24 months, respectively 
(Rosen, Fox & Gill, 2007). The main cause of attrition was loss to follow up, accounting for 
56% of the attrition.  Death accounted for 40% of attrition.   
 
2.5 CONCLUSION 
In the review of literature, it has emerged that the best measure of adherence to HAART is 
monitoring the viral load. CD4 cell count monitoring has been used as a surrogate measure of 
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adherence in settings where viral load was not done. Weight gain has not been found to 
correlate well with adherence. Studies in Africa have shown high levels of adherence to 
HAART but as programmes scale-up there could be a risk of lower adherence levels. 
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CHAPTER 3 
AIMS AND OBJECTIVES 
3.1 AIM OF THE STUDY 
The aim of the study was to describe adherence to HAART and factors influencing adherence 
among patients in Keetmanshoop district.  
 
3.2 OBJECTIVES  
1. To describe levels of adherence to HAART amongst clients at Keetmanshoop ART clinic. 
2. To describe changes in CD4 counts and body weight of clients on HAART over a 12 
month period. 
3. To investigate factors associated with adherence to HAART.  
4. To analyse associations between CD4 count and adherence. 
5. To analyse associations between changes in body weight and adherence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2655201 
 
20 
 
CHAPTER 4 
RESEARCH DESIGN AND METHODOLOGY 
 
4.1 STUDY DESIGN 
A descriptive cross-sectional survey was done. The researcher chose a cross-sectional study 
design as this type of design has a short time frame and therefore lower cost implications 
(Beaglehole, Bonita & Kjellstrom, 2000).There is also no risk of loss to follow-up of study 
participants since data is collected at one point (Beaglehole et al, 2000).  
 
4.2 STUDY POPULATION 
By end of December 2007, there were 675 adult clients registered on HAART at the 
Keetmanshoop ART clinic. The eligibility criteria for the study population was being 18 
years and older, and on HAART for at least one year.  
 
4.3 SAMPLING 
From the study population of 675 clients, assuming an expected optimal adherence rate of 
95% and a worst acceptable rate of 90% (i.e. 5% margin of error), at 99% level of 
confidence, a sample of 106 clients was calculated using Epi-Info’s StatCalc statistical 
program. All clients attending the clinic who met the inclusion criteria were recruited into the 
study sequentially until the sample size was met. 
 
4.4 PILOT STUDY 
A pilot study was done on 10 clients at the clinic to pre-test the questionnaire. The pre-test 
served to assess the quality of the questionnaire, and the understanding of the questions.  
During the pre-test running of the interviews, it was realised that clients who were already 
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well-established on treatment did not bring their pills for the pill count. Also only at the 
pharmacy would they be able to establish if the pill count was corresponding to amount 
expected. Pill counts were therefore abandoned as a measure of adherence in this study, and 
only adherence to appointments was used. The question items asking about the partner status 
and whether they are on HAART were removed from the initial questionnaire because some 
of the clients in the pilot study were not comfortable with these questions. 
 
4.5 DATA COLLECTION 
Data collection started on the 9th of March, 2009 and ended on the 16th of April, 2009. A 
questionnaire was administered to clients attending the clinic who met the inclusion criteria. 
The questionnaire collected demographic data and data on source of referral to ART clinic, 
reminder tools, knowledge about HIV treatment, knowledge about consequences of poor 
adherence, disclosure levels and alcohol use. The client’s file was then reviewed by the 
researcher to collect data on baseline, 6 month and 12 month CD4 cell counts and body 
weight (Appendix 1). 
 
4.6 DATA MANAGEMENT AND ANALYSIS  
The questionnaires were checked for completeness by the researcher and the data was 
captured in Microsoft access 2000. The data was then imported into the program EpiInfo 
version 3.3 for analysis. The frequencies of the demographic characteristics, source of 
referral to ART clinic, reminder tools, knowledge about HIV treatment, knowledge about 
consequences of poor adherence and disclosure levels were analysed using EpiInfo version 
3.3. Graphs were drawn using Microsoft Office Excel 2007 while the tables drawn manually. 
Summary statistics of the continuous variables of age, CD4 counts and body weight were 
done using EpiInfo version 3.3 to calculate the median and interquartile range. Bivariate 
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analysis using two by two tables and calculation of chi-square was done to analyse 
correlations between adherence and the variables of sex, alcohol use, distance from clinic, 
disclosure to family members and disclosure to friends.  
 
4.7 VALIDITY 
4.7.1 SELECTION BIAS 
The research was recruiting clients who were attending the ART clinic to participate in the 
study. This group of clients who keep their appointments may have better adherence levels 
than those likely to miss their appointments. The study also missed those who may have been 
lost to follow-up. By only recruiting those clients attending the clinic, the study may have 
selected clients who have good levels of adherence and missed those with poor adherence and 
lost to follow-up. 
 
4.7.2 MEASUREMENT BIAS 
The clients covered in the study had started their antiretroviral treatment between October, 
2003 and March, 2008. There were some shortcomings in the record-keeping in the period 
2003-2006 and some records did not have the 6 and 12 month CD4 and body weight values. 
The values missing were few and did not adversely affect the total quality of the CD4 and 
body weight data. The questionnaire was in English language. The interviewers were trained 
prior to data collection and were able to understand the questions adequately. The 
interviewers then translated and asked the questions in the local languages and this had a 
potential for measurement bias.  
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4.7.3 CONFOUNDING  
Adherence to any long-term treatment is often influenced by various factors in a person’s life 
(Kagee, 2004). These could be social, medical or psychological factors. Some of the known 
confounding factors could be depression and other undiagnosed psychiatric illnesses, 
substance abuse, and the degree of support a client has from family, friends or support 
groups.  
  
4.7.4 RELIABILITY  
 A post-test of the data collection tool was not done for this study due to time and cost 
constraints. Reliability could therefore not be assessed for this study.  
 
4.7.5 GENERALISABILITY 
The sample in this study was clients who access antiretroviral therapy through the public 
health sector in Keetmanshoop. It can probably be generalised to other clients in Namibia 
accessing antiretroviral therapy in the public health sector in other districts with similar 
characteristics to Keetmanshoop. 
 
4.8 ETHICAL CONSIDERATIONS 
Ethics in research is based on the principles of respect of persons, beneficence, non-
maleficence and justice for all persons (Bankowski, Bryant & Last, 1991). A research 
proposal should be submitted to an ethics body to ensure that the research conforms to 
acceptable scientific and ethical standards (Bankowski et al, 1991). In this study, ethical 
clearance to conduct the research was granted by the Ethics Committee of The University of 
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the Western Cape. Permission to conduct research was also granted by the Ministry of Health 
and Social Services, Namibia.  
 
Persons being requested to participate in a research should have full information on the 
research and its implications to them and their communities to enable them make an informed 
decision on participation in research (Bankowski et al, 1991). The purpose and nature of this 
research was explained to all participants by the interviewers. Each client was given a 
participant information sheet which provided further information on the research and the right 
of the participants to decline to answer any questions or to withdraw from the research at any 
time. The participant information sheet also guaranteed participant confidentiality. Each 
participant who volunteered for the study signed a consent form. The questionnaires did not 
bear any names and there was no linkage between the questionnaire and the consent form. 
The identity of the study participants was therefore protected and kept confidential. The 
participants were assured that the information gathered was to be used for research purposes 
only for the mini-thesis.  
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CHAPTER 5 
RESULTS 
 
5.1 SAMPLE SIZE AND RESPONSE RATE 
A sample of 106 was realised for the study. Response rate was 100% as all clients 
approached to participate in the study agreed to participate. However during data cleaning 4 
of the questionnaires were found not to meet the study criteria and were therefore not used in 
the analysis. Three clients had been on treatment for less than 1 year and one client was 17 
years old. One other questionnaire was also not used for analysis because this was a client 
who was attending the clinic for the first time as a transfer-in from another facility. He did 
not bring his transfer letter along and there was therefore no clinical record for him. The other 
101 questionnaires were used for analysis. 
 
5.2 DEMOGRAPHIC CHARACTERISTICS OF RESPONDENTS. 
More women (63.4%) than men (36.6%) participated in the study (Figure 1). The respondents 
ranged from 18 years to 63 years with a median age of 40 years (Interquartile range [IQR] 
34-46 years). 
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Figure 1. Age distribution of respondents by gender 
 
Slightly less than two thirds (63%) of respondents were single and about a quarter were 
married (23%) (Table 1). Two respondents were divorced and a small proportion of 
respondents was co-habiting (6%) and widowed (5%).  
 
Most (87%) of the respondents had either primary school education (47%) or secondary 
school education (40%). A small proportion (13%) had no schooling and none had tertiary 
education. Unemployment was high (53%), with only a third (33%) being permanently 
employed. A small proportion (13%) had seasonal employment and one respondent was self-
employed. Most (72.8%) of the respondents lived within a radius of 10km of Keetmanshoop 
town. About a third (30%) of the respondents were members of a support group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2655201 
 
27 
 
Table 1. Demographic characteristics of respondents 
 
Variable  Males (%) Females (%) Totals (%) 
 
Educational level 
No schooling  
Primary 
Secondary 
 
Marital status 
Single 
Married  
Divorced 
Live-in partner 
Widowed 
 
Employment status 
Permanent 
Seasonal 
Self-employed 
 Un-employed 
 
Distance to clinic 
>10km 
<10km 
 
Member of support 
group 
 
 
6 (16.2) 
19 (51.4) 
12 (32.4) 
 
 
22 (59.5) 
13 (35.1) 
1 (2.7) 
1 (2.7) 
0 
 
 
21 (56.8) 
5 (13.5) 
0 
11 (29.7) 
 
 
10 (27.0) 
27 (73.0) 
 
8 (21.6) 
 
 
7 (10.9) 
28 (43.8) 
29 (45.3) 
 
 
42 (65.6) 
11 (17.2) 
1 (1.6) 
5 (7.8) 
5 (7.8) 
 
 
13 (20.3) 
8 (12.5) 
1 (1.6) 
42 (65.6%) 
 
 
18 (28.1) 
46 (71.9) 
 
23 (35.9) 
 
 
13 (12.9) 
47 (46.5) 
41 (40.6) 
 
 
64 (63.3) 
24 (23.7) 
2   (1.9) 
6  (5.9) 
5  (5) 
 
 
34 (33.7) 
13 (12.9) 
1   (0.99) 
53 (52.5) 
 
 
28 (27.7) 
73 (72.3) 
 
31 (30.0) 
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5.3 SOURCE OF REFERRAL TO THE ART CLINIC 
The public health system was the main source of referral of respondents to the ART clinic, 
accounting for 67.3% of referrals (Figure 2). The respective departments that referred to the 
ART clinic were the Tuberculosis Control Programme (26.7%), the PMTCT programme 
(17.8%) and the hospital wards and peripheral clinics (22.8%). About a quarter (26.7%) of 
the respondents was self-referred and a small percentage (5.9%) was referred from a local 
non-governmental organisation (the New Start Centre). 
 
 
Figure 2. Source of referral of clients to the ART clinic 
 
5.4 SOURCE OF LINKAGE TO SUPPORT GROUPS 
Most respondents had been linked to support groups from the family (54.4%). Other sources 
of linkage to support groups were the church (21.1%) and health workers (17.5%). 
 
 
 
 
2655201 
 
29 
 
  
Figure 3. Source of linkage to support groups 
 
5.5 INFORMATION AND KNOWLEDGE ABOUT HIV AND HIV TREATMENT 
5.5.1 SOURCE OF INFORMATION  
The main source of information about HIV and HIV treatment were health workers (73.3%) 
followed by the media (20.7%), family and friends (16.8%) and from the church (5%) (Figure 
4). Some respondents reported more than one source of information.  
 
Figure 4. Source of information about HIV and HIV treatment 
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5.5.2 KNOWLEDGE ABOUT HIV TREATMENT 
Most respondents were aware that HIV treatment reduces the amount of the HI virus (67.3%) 
and makes the body strong (59.4%) (Figure 5). Only one respondent said the treatment kills 
HIV, one responded that it cures HIV and one did not know how the treatment worked.  
 
 
Figure 5. Knowledge about HIV treatment 
 
 
5.5.3 KNOWLEDGE ABOUT CONSEQUENCES OF POOR ADHERENCE  
Asked what would happen if one did not take treatment regularly, most respondents (62.4%) 
knew that one would get sick, while slightly less than half knew that the HIV infection would 
get worse (43.6%) and that one would become resistant to medicines (42.6%) (Figure 6). One 
responded that he would die. 
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Figure 6. Knowledge about consequences of poor adherence 
 
 
5.6 REMINDER TOOLS FOR HAART  
The study participants were asked what resources they use to remember to take their 
treatment on time. Their responses included – alarm on watch, news on radio, a television 
programme, setting cellphone reminders, alarms on clock, and having family members 
remind them (Table 2). One participant took his treatment when reporting for his work shift. 
Three clients did not give any reminder tool. More than half (56.4%) of respondents had 
more than one reminder tool.  
 
Table 2. Reminder tools 
 
Reminder tool Percentage of respondents  
Watch/clock 
Family member 
Cellphone reminder 
Radio programme 
None  
Work schedule 
59.4 
36.6 
23.8 
17.8 
3 
1 
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5.7 DISCLOSURE OF HIV STATUS 
Most respondents (98%) had disclosed their HIV status to at least one person (Figure 7). Only 
two respondents had not disclosed their status to anybody. The respondents had higher levels 
of disclosure within the family than among the friends. Half of the respondents (50%) had 
disclosed their status to all the family members but only slightly less than a third (28%) had 
disclosed to all their friends.  
 
 
Figure 7. Level of disclosure of HIV status among family or friends 
 
5.8 ADHERENCE 
Adherence was measured as the percentage of the appointments kept in the year preceding 
the study. 100% adherence was defined as coming for all the appointments within one week 
of the appointment date. 90% adherence was defined as missing not more than two 
appointments in the year but coming for a follow-up within a fortnight of the missed 
appointment. Most (86.1%) study participants kept 90% or more of their appointments and 
were classified as having optimal adherence (Figure 8).  
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Figure 8. Adherence levels 
 
5.9 CD4 CELL COUNTS AND BODY WEIGHT OF RESPONDENTS 
The median CD4 cell count of the study participants at the start of treatment was 126 cells/μl 
 (Interquartile range [IQR] 79-178) (Figure 9). The median CD4 cell count increased to 279 
cells/μl (IQR 161-414) at 6 months and 304 cells/μl (IQR 220-464) at 12 months. The 
median CD4 cell count of the most recent result available for the respondents was 366 cells/ 
μl (IQR 257-465).  
 
Figure 9. Median CD4 cell counts  
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The median body weight of study participants at start of treatment was 50 kg (IQR 44-60). 
This  increased to 56kg (IQR 48-66) at 6 months (IQR 50-67) and 57kg at 12 months (Figure 
10). The median body weight of the respondents at the time of the study was 58kg (IQR 50-
67). 
 
 
Figure 10. Median body weight of study participants 
 
5.10 CD4 CELL COUNTS AND ADHERENCE 
The median CD4 cell counts were stratified for adherence level to determine if there was any 
association between CD4 cell counts and adherence (Figure 11). Respondents who had 
optimal adherence over the past year showed steady increases in CD4 cell counts while 
respondents who had sub-optimal adherence showed inconsistent increases in the CD4 cell 
counts. 
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Figure 11. Median CD4 cell counts by adherence  
 
5.11 BODY WEIGHT AND ADHERENCE 
The median body weight was also stratified for adherence level to determine if there was any 
association between body weight and adherence (Figure 12). Respondents who had optimal 
adherence over the past year showed a steady increase in body weight while respondents who 
had sub-optimal adherence showed inconsistent body weight gain. 
 
Figure 12. Median body weight by adherence 
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5.12 FACTORS ASSOCIATED WITH ADHERENCE TO HAART    
 
The variables sex, alcohol use, distance from clinic, disclosure to more than 5 family 
members and disclosure to more than 5 friends were tested for associations with adherence 
using the Chi-square test (Table 3). Only distance from clinic was found to be statistically 
associated with adherence. Participants who lived more than 10 kilometres away from the 
clinic were 1.47 (95% C.I. 1.11-1.95) times more likely to have sub-optimal adherence.  
 
Table 3. Factors associated with suboptimal adherence 
 
Variable  Risk Ratio (95% C.I.) Chi-square P value 
 
Sex=female 
 
Uses Alcohol  
 
Lives >10km from 
clinic  
 
Disclosed to more than 
5 family members  
 
Disclosed to more than 
5 friends 
 
1.04 (0.88-1.16) 
 
0.96 (0.77-1.2) 
 
1.47 (1.11-1.95) 
 
 
0.99 (0.85-1.16) 
 
 
0.94 (0.78-1.14 
 
0.27 
 
0.14 
 
15.3 
 
 
0.00 
 
 
0.38 
 
0.40 
 
0.47 
 
0.00 
 
 
0.59 
 
 
0.36 
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CHAPTER 6 
DISCUSSION  
 
6.1 DEMOGRAPHIC CHARACTERISTICS 
The response rate of this study was very good as all the clients who were approached for the 
study agreed to take part. In this study there were more women than men in a ratio of about 
2:1. This is also reflected in the Namibian national enrolment for HAART where women 
have a ratio of about 2:1 to men (MOHSS, 2007). It is also the case in other studies in Africa 
where there are more women enrolled in HIV treatment in the public sector than men, for 
example in a study in Uganda study there were 37% of men compared to 63% of women 
(Nakiyemba et al, 2004).  A South African study in Khayelitsha had a female enrolment of 
70% while a Mozambique study had a female enrolment of 55% (Coetzee et al, 2004; 
Marazzi et al, 2006). At two public health facilities offering HAART in Gauteng, South 
Africa the female enrolment was 73.5% (Kigozi, 2008).  
 
This higher female enrolment in public ART programmes could be explained by the fact 
women are more likely to interact with the health services more often than men as they attend 
antenatal services and family planning services (Kigozi, 2008). This increases their 
opportunity to access HIV care. In this study 17.8% of respondents were referred from the 
PMTCT services, all women. Another reason for lower male enrolment in the public sector 
ART services could be that employment levels are higher in men and they could be accessing 
HAART through work-based programmes.     
 
The age distribution of the study participants peaked at 30-39 years in females and 40-49 
years in males. This has also been found to be the age group with the highest prevalence of 
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HIV. During the Namibian 2008 National Testing Day the HIV prevalence was highest in the 
30-44 age groups (MOHSS, 2008b). 
 
Most of participants had primary and secondary education. There were no participants with 
tertiary education in this study. Enrolment in tertiary education is low in the Karas region as 
seen in the 2006-2007 NDHS.  In that survey there were only 4.4 and 4.1% women and men 
with tertiary education respectively in the Karas region (MOHSS, 2008a). The 
unemployment rate in this study was 65.6% for women and 29.7% for men. This was also 
seen in the 2006-2007 NDHS where women had a higher unemployment rate of 41.1% in 
Karas region at the time of the survey compared to 25.1% for men (MOHSS, 2008a). 
 
About a quarter of the study participants had been referred for HAART from the tuberculosis 
(TB) programme. This underscores the importance of TB as a major opportunistic infection 
in HIV- infected individuals, especially in areas with a high TB burden. Self-referral to the 
ART clinic in this study was 26.7 %. A further 5.9% of participants had come from a local 
NGO which offers VCT. This translates into 32.6% of participants who initiated HIV testing 
through VCT and were able to start antiretroviral therapy. Knowing one’s HIV status is an 
important first step in the control of HIV. For those who test negative, the prevention 
message is reinforced and they can be motivated to remain negative. For those who test 
positive it will be an entry point into comprehensive care and they will also be counselled on 
risk reduction to avoid re-infection. VCT has been found to be efficacious in reducing HIV 
transmission. In a randomised controlled study in three countries, Kenya, Tanzania and 
Trinidad and Tobago, individuals and couples who received VCT interventions had 
significant reductions of unprotected sex at the first follow up compared to the group that 
received health education only (Center for AIDS Prevention Studies, 2000). 
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6.2 ADHERENCE AND FACTORS ASSOCIATED WITH ADHERENCE 
Adherence to HAART in this study was fair with 86.1% of participants showing optimal 
adherence. However, a sub-optimal adherence rate in the study was 13.9% and this is higher 
than the acceptable level of <5%.is not acceptable and the ART programme needs to address 
this. This level of optimal adherence is comparable with studies in other parts of Africa. In 
the Senegalese study 88% of clients had good adherence levels while three studies in South 
Africa have found 88%, 93.5% and 89% of clients having optimal adherence levels 
respectively (Nachega et al, 2004; Orrell et al, 2003; Kigozi, 2008). In the meta-analysis of 
studies on adherence by Mills (2006) and others, African studies showed adherence levels of 
77%. 
 
These fair levels of adherence in Keetmanshoop could be explained by various factors that 
could be impacting on adherence. Alcohol use and substance abuse has been shown in other 
studies to affect adherence (Stone, 2002). Though alcohol abuse is a major problem in the 
district, alcohol use among the study participants was found to be very low and did not 
impact on adherence. Knowledge about HIV and HIV treatment was also high among the 
study participants. The study participants also had good knowledge about the consequences 
of poor adherence. The health system is still the main source of information about HIV and 
HIV treatment. Other sources of information included the media, family members and the 
church. Educational interventions that improve knowledge have been shown to impact 
positively on adherence, as seen in the study by Goujard (2003) and others. In a study in 
Uganda, the radio was one of the main sources of information on HIV/AIDS (Nakiyemba et 
al, 2004). A radio health education program was started in Keetmanshoop district in 2007 
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(Keetmanshoop DCC, 2008). This programme gives information about HIV/AIDS among 
other health issues. 
 
About thirty seven percent (37%) of the respondents had family members remind them about 
taking their treatment. Apart from family members reminding them, study participants also 
used watches (59%), radios (37%) and cell phones (24%) as reminder tools. Most 
respondents (56.4%) relied on more than one reminder mechanism. This strategy of pegging 
of treatment to daily routines like listening to news or reporting for work has been seen in 
other studies like in Tanzania or in Belgium among care givers for children on HAART (Watt 
et al, 2008; Hammami et al, 2004). Routinizing of pill-taking is one of the strategies that 
impact positively on adherence.  
 
The use of family and social support in this study compares well with other studies in Africa 
which have shown that family and social support plays an important role in PLWHA 
adhering to their antiretroviral treatment. In the Uganda study clients reported that family 
members helped with support for adherence (Nakiyemba et al, 2004). The study by Ware and 
others (2009) showed social capital playing a major role in patients’ adherence to HAART.  
In Tanzania material and emotional support from others was one of the factors that facilitated 
adherence. Using more than one reminder tool may also have contributed to the good 
adherence levels in this study.  
 
A quarter of the study participants had used cell phones as part of their reminder tools in this 
study. The use of cell phones has increased exponentially in Africa in the past ten years and it 
is estimated that about 60% of adults in Africa now own cell phones (Lehr, 2005). Cell 
phones are not only used as a means of communication but also as a source of information 
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and for facilitating trade in Africa’s informal sector. Airtime has been used for barter trade 
and for transfer of currency (Lehr, 2005). In Namibia, the largest cellular network – Mobile 
Telecommunications Limited (MTC) recently celebrated one million customers. In a country 
with a total population of about 2 million, this translates into a very high coverage. The use of 
cell phones and cellphone tracking technology as a drug-tracking, patient monitoring and 
reminder tool for HAART is an avenue that is already being explored (Microsoft research, 
2009). 
 
Thirty percent (30%) of the participants were also members of community support groups. 
Knowledge of support groups in the area was low at 46.5%. Of those participants who knew 
about support groups, most had learned about the groups from family (54.4%) and the church 
(21.1%). Only 17.5% of participants had learned about support groups from the health 
workers. This low level of knowledge of local support groups had also been seen in Kenya, 
where at the start of a HAART-DOT program, researchers found that almost two thirds of 
people had not heard of the local support groups (Sarna, Hawken & Kaai, 2004). A study in 
Gauteng, South Africa, also found very low levels of membership of support groups (Kigozi, 
2008). Fear of the community members knowing one’s HIV status and risking stigma or 
discrimination may influence people’s willingness to join support groups.  
 
6.3 CD4 CELL COUNT AND BODY WEIGHT CHANGES 
The median CD4 cell count at start of therapy in this study was 126 cells/μl 
. In Namibia the criteria for starting HAART in adults is a CD4 cell count of 200 or below or 
WHO stage 3 or 4 disease (MOHSS, 2007). Most people therefore start antiretroviral therapy 
with advanced HIV disease and a negative body weight balance. The respondents 
experienced significant weight gain in the first six months. The median body weight 
increased by 6kg after 6 months of treatment. However the body weight gain levels off as 
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respondents reach their expected body weight. In respondents with optimal adherence the 
body weight gain was maintained but the respondents with poor adherence were not able to 
maintain their body weight gain and experienced weight loss by 12 months. 
 
The immunological response of the study participants was good as seen in the increase in the 
median CD4 cell counts. Participants in this study showed improvements in their indices with 
the median CD4 cell count doubling by 6 months and increasing to 304 cells/μl by 12 months 
from a baseline of 126 cells/µl. The initial CD4 cell count recovery was good in all the 
respondents up to 6 months. However responds with sub-optimal adherence were not able to 
maintain the CD4 increases and experienced a decrease of CD4 cell counts by 12 months. 
Respondents with optimal adherence had a sustained increase in their CD4 cell counts.  
 
Patients in other African settings have also started HAART with advanced disease and shown 
good immunological responses to therapy. Most patients in treatment programmes in Africa 
start therapy with CD4 cell counts of less than 200 cells/μl. Patients in Senegal had a median 
increase of 180 cells/μl by 18 months (Laurent et al, 2002). In South Africa, the Soweto 
study saw an increase of CD4 cell counts from 200 cells/μl at baseline to 324 cells/μl while 
the Khayelitsha study had an increase of 288 cells/μl by 18 months from a baseline of 43 
cells/μl (Nachega et al, 2004; Coetzee et al, 2004).   
 
6.4 STUDY LIMITATIONS 
Measurement of adherence to medication by adherence to appointments is an imprecise 
measure and the measured level of adherence may be a crude estimate of the real adherence 
level.  The study also assessed the CD4 cell counts and body weight of the participants. CD4 
cell counts are acceptable surrogate markers for viral loads but changes in body weight have 
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been shown to correlate poorly with viral loads or CD4 cell count changes. In this study 
information on adherence and other study variables was collected at the same time, therefore 
temporal association between adherence and other variables could not be fully described. 
This limited the study in making causal inference about adherence.  
 
This study was also limited in that it only covered clients who are attending the clinic. By 
focusing only on clients attending the clinic, the study misses out on an important group of 
clients who may be poor adherers and not attending clinic regularly, or who may have 
defaulted therapy. This could result in an artificially high level of adherence. The study 
period was also limited as data was collected over a one month period. Seasonal variations of 
attendance at the clinic were not accounted for though this could have an influence on 
findings. 
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CHAPTER 7 
CONCLUSION AND RECCOMENDATIONS 
 
This study set out to determine adherence levels at Keetmanshoop and factors that could 
influence adherence. The study found that most clients at Keetmanshoop ART clinic were 
aware about the risks associated with poor adherence. The study also found that clients on 
HAART use several strategies to help them remember to take their medicines.  This could 
partly explain the good adherence levels among the respondents. The study found that of 
those clients who are attending the clinic, adherence levels were good with 86.1% of 
respondents having optimal adherence.  
 
The study also demonstrated that the clients on HAART experienced immunological and 
clinical recovery with increases in the CD4 cell count and body weight gain. The study found 
that adherence levels have an impact on CD4 cell count and body weight. Sub-optimal 
adherence was associated with falling CD4 cell counts and weight loss.  This correlation 
between adherence levels and CD4 cell count demonstrates that in settings where viral load 
testing cannot be done, CD4 cell counts could be used as a measure of adherence. 
 
The study found that distance from the clinic to be the only factor significantly associated 
with adherence. The Keetmanshoop ART programme will need to address the issue of 
adherence in patients who live far from the clinic. This can be done by incorporating ART 
services in the Primary Health Care (PHC) services and providing these services at the PHC 
clinics in the district. The ART services should also be incorporated in the district outreach 
services to further improve access to the services. 
 
 
 
 
 
2655201 
 
45 
 
REFERENCE LIST 
 
Abaasa, A.M., Todd, J., Ekoru, K., Kalyango, J.N., Levin, E., Odeke, E. & Karamagi, C.A.S. 
(2008). Good Adherence to HAART and Improved Survival in a Community HIV/AIDS 
Treatment and Care Programme: The Experience of The AIDS Support Organization 
(TASO), Kampala, Uganda. BMC Health Services Research, 8: 241 [Online], Available: 
http://www.biomedcentral.com/html [Downloaded 03/05/09 10:41 PM] 
 
Bangsberg, D.R., Perry, S., Charlebois, E.D., Clark, R.A., Robertson, M., Zolopa, A.R. & 
Moss, A. (2001). Non-Adherence to Highly Active Antiretroviral Therapy Predicts 
Progression to AIDS. AIDS, 15 (9): 1181-1183. [Online], Available: 
http://www.aidsonline.com/html   [Downloaded  09/05/08 09:43 PM] 
 
Bankowski, Z., Bryant, J.H. & Last, J.M.  (1991). Ethics & Epidemiology: International 
Guidelines. [Online], Available: http://www.who.org/pdf  [Downloaded 28/08/08 06:28 PM] 
 
Beaglehole, R., Bonita, R. & Kjellstrom, T. (2000). Basic Epidemology. WHO, Geneva.  
 
Bisson, G.P., Gross, R., Bellamy, S., Chittams, J., Hislop, M., Regensberg L., Frank, I., 
Maartens, G. & Nachega, J.B. (2008). Pharmacy Refills Adherence Compared with CD4 
Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy.  PLoS Med, 5 
(5): e109 [Online], Available: http://www.plosmedicine.org/html [Downloaded 01/06/09 
09:50 PM] 
 
 
 
 
 
2655201 
 
46 
 
Boyle, B.A. (2000). HAART and Adherence. AIDS Read, 10 (7): 392-296 [Online], 
Available: http://www.medscape.com/html [Downloaded 25/07/08 11:03 PM] 
 
Brinkof, M.W.G., Boulle, A., Weigel, R., Messou, E., Mathers, C., Orrell, C.,Dabis, F., 
Pascoe, M. & Egger, M. (2009). Mortality of HIV-Infected Patients starting Antiretroviral 
Therapy in Sub-Saharan Africa: Comparison with HIV-unrelated Mortality. PLoS Med, 6 (4): 
e1000066 [Online], Available: http://www.plosmedicine.org/html [Downloaded 03/06/09 
09:42 PM] 
 
Cameron, E. & Gupta, A. (2002). Global Access to Treatment: Achievements and 
Challenges. Canadian HIV/AIDS Policy and Law Review, 7 (1). [Online], Available: 
http://www.aidslaw.ca/html [Downloaded 24/02/06 10:20 PM] 
 
Center for AIDS Prevention Studies. (2000). The Voluntary HIV-1 Counselling and Testing 
Efficacy Study: A Randomized Controlled Trial in Three Developing Countries. [Online], 
Available: http://www.caps.ucsf.edu/pdf [Downloaded 20/07/06 04:52 PM] 
 
Coates, J.T. (2003). What is the Role of Adherence in HIV Treatment? [Online], Available: 
http://www.caps.ucsf.edu/html [Downloaded 25/08/08 09:55 PM] 
 
Coetzee, D., Boulle, A., Hildebrand, K., Asselman, V., Cutsem, G. & Goemaere, E. (2004). 
Promoting Adherence to Antiretroviral Therapy: The Experience from a Primary Care Setting 
in Khayelitsha, South Africa. AIDS, 18 (Suppl 3): S27-S31 [Online], Available: 
http://www.aidsonline.com/pdf   [Downloaded 05/02/08 11:32 PM] 
 
 
 
 
 
2655201 
 
47 
 
Dixon, S., McDonald, S. & Roberts, J. (2002). The Impact of HIV & AIDS on Africa's 
Economic Development. The British Medical Journal, 324: 232-234 [Online], Available: 
http://www.bmj.com/html [Downloaded 01/06/09 9:43 PM] 
 
Duran A.J. (2004). The Individual Social Assessment of Predictive Adherence to HAART as 
a Fundamental Tool in the Therapeutic Success of People Living with AIDS. International 
Conference on AIDS, 15: Abstract no. TuPeD5188 [Online], Available: 
http://www.ncbi.nlm.nih.gov/html [Downloaded 25/08/08 09:26 PM] 
 
Economic Commission of Africa. (Undated). Africa: The Socio-Economic Impact of 
HIV/AIDS. [Online], Available: http://www.uneca.org/pdf [Downloaded 04/04/09 05:24 PM]  
 
Eholie, S.P., Bissagnene, E., Gaumon, A., Mambo, J., Guiza, J., Kakou, A. & Kadio, A. 
(2002). The Social Economic Impact of HIV/AIDS Infection and Investment in Antiretroviral 
Therapies (ARV’s) on a Private Company in Abidjan, Cote d’Ivoire. International 
Conference on AIDS, 14: Abstract no. MoOrB1096 [Online], Available: 
http://www.ncbi.nlm.nih.gov/html [Downloaded 01/06/09 09:48 PM]  
 
Eholie, S.P., Tanon, A., Polneau, S., Ouiminga, M., Djadji, A., Kangah-Koffi, C., Diakite, N., 
Anglaret, X., Kakou, A. & Bissagnene, E. (2007). Field Adherence to Highly Active 
Antiretroviral Therapy in HIV-infected Adults in Abidjan, Cote D’Ivoire. Journal of 
Acquired Immune Deficiency Syndromes, 45 (3): 355-358.  [Online] Available: 
http://www.ncbi.nlm.nih.gov/html [Downloaded 22/04/08 10:30 PM]  
 
 
 
 
 
2655201 
 
48 
 
Feldbaum, H., Lee, K. & Patel, P. (2006). The National Security Implications of HIV/AIDS. 
PLoS Med, 3 (6): e171 [Online], Available: http://www.plosmedicine.org/html [Downloaded 
01/06/09 10:05 PM] 
 
Gill, C.J., Hamer, D.H., Simon, J.L., Thea, D.M. & Sabin, L.L. (2005). No Room for 
Complacency about Adherence to Antiretroviral Therapy in Sub-Saharan Africa. AIDS, 19 
(12): 1243-1249. [Online], Available: http://www.aidsonline.com/html  [Downloaded 
20/04/08 09:50 PM] 
 
Global Action for Children. (2009). Global Action for Children: Fighting  for Orphans and 
Vulnerable children. [Online], Available: http://www.globalactionforchildren.org/html 
[Downloaded 04/08/09 09:33 PM] 
 
Goujard, C., Bernard, N., Sohier, N., Peyramond, D., Lancon, F., Chwalow, J., Arnould, B. & 
Delfraissy, J. (2003). Impact of a Patient Education Program on Adherence to HIV 
Medication: A Randomized Clinical Trial. Journal of Acquired Immune Deficiency 
Syndromes, 34:191-194. [Online], Available: www.jaids.org/pdf [Downloaded 07/04/09 
10:15 PM] 
 
Hammami, N., Nostlinger, C., Hoeree, T., Lefevre, P., Jonckheer, T. & Kolsteren, P. (2004). 
Integrating Adherence to Highly Active Antiretroviral Therapy into Children’s Daily Lives: 
A Qualitative Study. Paediatrics, 114 (5): e591-e597 [Online], Available: 
http://www.paediatrics.org/pdf [Downloaded 25/08/09 09:40 PM] 
 
 
 
 
 
2655201 
 
49 
 
Hill, Z., Kendall, C. & Fernandez, M. (2003). Patterns of Adherence to Antiretrovirals: Why 
Adherence has no Simple Measure. AIDS Patient Care and STDs, 17 (10): 519-525. [Online], 
Available: www.liebertonline.org/pdf [Downloaded 22/07/08 09:26 PM] 
 
Hoffman, C., Rockstrol, J. & Kamps, B. (2005). HIV Medicine 2005. [Online], Available: 
http://www.HIVMedicine.com/pdf  [10/03/06 09:06PM]   
 
Kagee, A. (2004). Treatment Adherence in South African Primary Health Care. SA Fam 
Pract, 46 (10): 26-30 
 
Keetmanshoop Health District Coordinating Committee. (2008). Keetmanshoop Health 
District Annual Report. Keetmanshoop State Hospital, Keetmanshoop. 
 
Kigozi, L.J. (2008). Client Factors Determining ARV Adherence in Natalspruit Hospital and 
Impilisweni CHC in Gauteng Province in 2006. [Online], Available: 
http://www.wits.ac.za/pdf  [Downloaded 23/05/09 09:03 PM] 
 
Koenig, SP., Leandre, F., Farmer, P. (2004). Scaling up Treatment Programmes in Resource-
Limited Settings: The Rural Haiti Experience. AIDS, 18 (Suppl 3): S21-S25 [Online], 
Available: http://www.aidsonline.com/pdf   [Downloaded 06/02/08 09:47 PM] 
 
Laurent, C., DiaKhate, N., Gueye, N.F.N., Toure, M.A., Sow, P.S., Faye, M.A., Gueye, M., 
Ianrece, I., Kane, C.T., Liegeois, F., Vergne, L., Mboup, S., Badiane, S., Ndoye, I. & 
Delaporte, E. (2002). The Senegalese Government’s Highly Active Antiretroviral Therapy 
Initiative: An 18-Month Follow-Up Study. Journal of Acquired Immune Deficiency 
 
 
 
 
2655201 
 
50 
 
Syndromes, 16: 1363-1370. [Online]. Available: http://www.jaids.com/pdf  [Downloaded: 
05/02/08 11:48 PM] 
 
Laniece, I., Ciss, M., Desclaux, A., Diop, K., Mbodj, F., Ndiaye, B., Sylla, O., Delaporte, E. 
& Ndoye, I. (2003). Adherence to HAART and its Principal Determinants in a Cohort of 
Senegalese Adults. AIDS, 17 (3). [Online], Available: http://www.aidsonline.com/html 
[Downloaded 22/04/08 10:16 PM] 
 
Lehr, D. (2005). Cell Phone Use Changes Life in Africa [Online], Available: 
http://www.mobileafrica.net/html [Downloaded 10/06/09 09:21 PM] 
 
Marazzi, M.C., Bartolo, M., Gialloreti, L.E., Germano, P., Guidotti, G., Liotta, G., SanLio, 
M.M., Mancinell, S., Madolo, M.A., Narciso, P., Perno, C.F., Scarcella, P., Tintisona, G. & 
Palombi, L. (2006). Improving Adherence to Highly Active Anti-Retroviral Therapy in 
Africa: The DREAM Programme in Mozambique. Health Education Research Theory & 
Practice, 21 (1): 34-42. [Online], Available: http://www.oxfordjournals.org/pdf [Downloaded 
20/04/08 10:10 PM] 
 
McNicholl, I.R. (2008). Strategies to Enhance Adherence, Reduce Costs And Improve Patient 
Quality of Life. Supplement to Journal of Managed Care Pharmacy, 14 (5). [Online], 
Available: http://www.amcp.org/pdf [Downloaded 03/04/09 08:50 PM] 
 
Microsoft Research. (2009). Cell Phone–Based System could Improve HIV/AIDS Drug 
Tracking. [Online], Available: http://www.cater.cs.nyu.edu/html  [Downloaded 27/06/09 
10:43 PM]  
 
 
 
 
2655201 
 
51 
 
 
Mills, E.J., Nachega, J.B., Bangsberg, D.R., Singh, S., Rachlis, B., Wu, P., Wilson, K., 
Buchan, I., Gill, C.J. & Cooper, C. (2006). A Systematic Review of Developed and 
Developing Nation Patient-Reported Barriers and Facilitators. PLoS Medicine, 3 (11): 2039-
2064. [Online], Available: http://www.plosmedicine.org/html [Downloaded 08/08/08 09:50 
PM] 
 
Mills, E.J., Nachega, J.B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., Rachlis, B., Wu, P., 
Cooper, C., Wilson, K., Guyatt, G.H. & Bangsberg, D.R. (2006). Adherence to Antiretroviral 
Therapy in Sub-Saharan Africa and North America: A Meta-analysis. JAMA, 296 (6): 679-
690. [Online]. Available: http://www.jama.com/pdf [Downloaded 20/04/08 09:35 PM] 
 
Ministry of Health and Social Services. (2009). Circular No.8 of 2009 – Interpretation of 
Routine Viral Load Monitoring of ART Patients. Windhoek. 
 
Ministry of Health and Social Services. (2008a). Namibia Demographic and Health Survey 
2006-2007. Windhoek. 
 
Ministry of Health and Social Services. (2008b). Report of the 2008 National HIV Sentinel 
Survey. Directorate of Special Programmes, Windhoek. 
 
Ministry of Health and Social Services. (2007). National Guidelines for Antiretroviral 
Therapy Second Edition. Directorate of Primary Health Care, Windhoek. 
 
 
 
 
2655201 
 
52 
 
Montaner, J.S.G., Hogg, R., Wood, E., Kerr, T., Tyndall, M., Levy, A.R. & Harrigan, P.R. 
(2006). The Case for Expanding Access to Highly Active Antiretroviral Therapy to Curb the 
Growth of the HIV Epidemic. The Lancet, 368: 531-536. 
 
Murphy, D.A., Robert, K.J., Martin, D.J., Marelich, W. & Hoffman, D. (2000). Barriers to 
Antiretroviral Adherence among HIV-infected Adults. AIDS Patient Care and STDs, 14 (1): 
47-58. [Online], Available www.liebertonline.org/pdf [Downloaded 22/07/08 10:08 PM] 
 
Nachega, J.B., Lehman, D.A., Hlatshwayo, D., Mothopeng, R.,Chaisson, R.E. & Karstaedt, 
A.S. (2005). HIV/AIDS & Antiretroviral Treatment Knowledge, Attitudes, Beliefs & 
Practices in HIV-Infected Adults in Soweto, South Africa. Journal of Acquired Immune 
Deficiency Syndrome, 38:196-201. [Online], Available: www.jaids.org/pdf [Downloaded 
07/04/09 10:15 PM] 
 
Nachega, J.B., Stein, D.M., Lehman, D.A., Hlathawayo, D., Mothopeng, R., Chaisson, R.E. 
& Karstaedt, A.S. (2004). Adherence to Antiretroviral Therapy in HIV-infected Adults in 
Soweto, South Africa. AIDS Research & Human Retroviruses, 20 (10): 1053-1056. [Online], 
Available: www.liebertonline.org/pdf [Downloaded 08/08/08 09:24 PM] 
 
Nakiyemba, A., Aurugai, D.A., Kwasa, R. & Oyabba, T. (2004) Factors that Facilitate or 
Constrain Adherence to Antiretroviral Therapy among Adults in Uganda: A Pre-Intervention 
Study. [Online], Available: http://www.who.int/pdf [Downloaded 02/03/09 10:23 PM] 
 
 
 
 
 
2655201 
 
53 
 
O’Reilly, K. (2005). Revitalising HIV Prevention in Africa: Linking with and Benefiting 
from the Developing Momentum for AIDS Treatment. MERA Medical Education Resource 
Africa, 19: v-vi. 
 
Orrell, C., Bangsberg, D.R., Badri, M. & Wood, R. (2003). Adherence is not a Barrier to 
Successful Antiretroviral Therapy in South Africa. AIDS, 17: 1369-1375 [Online], Available: 
http://www.aidsonline.com/html [Downloaded 22/04/09 10:16 PM] 
 
Osterberg, L. & Blaschke, T. (2005). Adherence to Medication. The New England Journal of 
Medicine, 353 (5): 487-497. [Online], Available: http://www.nejm.org/html [Downloaded 
21/04/08 10:05 PM] 
 
Pennington, J., Kanabus, A. & Pembrey, G. (2009).  AIDS Orphans. [Online], Available: 
http://www.avert.org/html [Downloaded 04/08/09 09:30 PM] 
 
Poppa, A., Davidson, D., Deutsch, J., Godfrey, D., Fisher, M., Head, S., Horne, R. & Sherr, 
L. (2003). British HIV Association (BHIVA)/British Association for Sexual Health and HIV 
(BASHH) Guidelines for the Provision of Adherence Support to Individuals Receiving 
Antiretroviral Therapy. [Online], Available: http://www.bhiva.org/html [Downloaded 
03/02/08 08:56 PM] 
 
Rosen, S., Fox, M.P. & Gill, C.J. (2007). Patient Retention in Antiretroviral Therapy 
Programs in Sub-Saharan Africa: A Systematic Review. PLoS Med, 4 (10): e298 [Online], 
Available: http://www.plosmedicine.org/html [Downloaded 05/05/09 09:50 PM] 
 
 
 
 
 
2655201 
 
54 
 
 
Sarna, A., Hawken, M. & Kaai, S. (2004). Acceptability of a Modified Directly Observed 
Therapy Approach to Improve Adherence to Antiretroviral Therapy. Horizons Research 
Summary. [Online], Available: http://www.popcouncil.org/html [Downloaded 21/08/08 02:40 
PM] 
 
Stone, E. (2002). Enhancing Adherence to Antiretrovirals: Strategies & Regimens. Medscape 
General Medicine, 4 (3). [Online], Available: http://www.medscape.com/html [Downloaded 
22/04/08 11:15 PM] 
 
Teshale, E.H., Hanson, D.L., Sulivan P.S. & Wolfe, M.I. (2004). Can Weight Gain be used as 
a Marker for Viral Load Response in HIV-Infected Patients following Initiation of Highly 
Active Antiretroviral Therapy (HAART)? International Conference on AIDS, 15: Abstract no. 
MoPeB3101. [Online], Available: http://www.gateway.nlm.nih.gov/html [Downloaded 
18/02/10 09:48 PM]  
 
The President’s Emergency Plan For AIDS Relief. (2008). 2008 Country Profile: Namibia. 
[Online], Available: http://www.pepfar.gov/html [Downloaded 07/08/08 09:44 PM] 
 
UNAIDS. (2008). 2008 Report on the Global AIDS Epidemic. [Online], Available: 
http://www.unaids.org/pdf [Downloaded 07/09/08 10:03AM] 
 
 
UNAIDS. (2003). Stepping Back from the Edge: The Pursuit of Antiretroviral Therapy in 
Botswana, South Africa and Uganda. [Online], Available: http://www.unaids.org/pdf   
[Downloaded 05/02/08 11:58 PM] 
 
 
 
 
2655201 
 
55 
 
Van Oosterhout, J.J., Bodasing, N., Kumwenda, J.J., Nyirenda, C., Mallewa, J., Cleary, P.R., 
De Baar, M.P., Schuurman, R., Burger, D.M. & Zylstra, E.E. (2005). Evaluation of 
Antiretroviral Therapy Results in a Resource-Poor Setting in Blantyre, Malawi. Tropical 
Medicine and International Health, 10 (5): 464-470. [Online], Available: 
www.ncbi.nlm.nih.gov/pdf [Downloaded 08/08/08 09:33 PM]  
 
Verweel, G., Rossum, A.M., Hartwig, N.G., Wolfs, T.F., Scherpbier H.J. & De Groot, R. 
(2002). Treatment with Highly Active Antiretroviral Therapy in Human Immunodeficiency 
Virus Type 1-Infected Children is associated with a Sustained Effect on Growth. [Online], 
Available: www.ncbi.nlm.nih.gov/pubmed  [Downloaded 18/02/10 09:33 PM]  
 
Ware, N.C., Idoko, J., Kaaya, S., Biraro, I.A., Wyatt, M.A., Agbaji, O., Chalamilla, G. & 
Bangsberg, D.R. (2009). Explaining Adherence Success in Sub-Saharan Africa: An 
Ethnographic Study. PLoS Medicine, 3 (11): 2039-2064. [Online], Available: 
http://www.plosmedicine.org/html [Downloaded 30/05/09 09:50 PM] 
 
Watt, M.H., Maman, S., Earp, J.A., Eng, E., Setel, P.W., Golin, C.E., Jacobson, M. (2008). 
“It’s All the Time in My Mind”: Facilitators of Adherence to Antiretroviral Therapy in a 
Tanzanian Setting. Social Science & Medicine, 68 (10): 1793-1800 [Online], Available: 
http://www.nbci.nlm.nih.gov/pubmed/html [Downloaded 18/06/09 11:03 PM] 
 
Weiser, S., Wolfe, W., Bangsberg, D., Thior, I., Gilbert, P., Makhena, J., Kebaabetswe, P., 
Dickenson, D., Kgosidialwa, M., Essex, M. & Marlink, R. (2003). Barriers to Antiretroviral 
Therapy Adherence for Patients Living with HIV infection and AIDS in Botswana. Journal 
 
 
 
 
2655201 
 
56 
 
of Acquired Immune Deficiency Syndromes, 34: 281-288. [Online], Available: 
www.jaids.org/pdf [Downloaded 07/08/08 10:15 PM] 
 
WHO. (2001). Adherence to Long-Term Therapies: Policy for Action. [Online], Available: 
http://www.who.int/pdf  [Downloaded 05/08/08 10:55 PM] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2655201 
 
57 
 
Appendix 1 
Q.no. _____________ 
 
Record Review 
 Baseline  6 months  12 months Latest  
CD4 cell count     
Weight      
 
Percentage of appointments kept in last one year: __________________  
 
Questionnaire 
How old are you: _______________________ 
Sex: __________________________________ 
Marital status: 
Married 
Single  
Separated/divorced  
Widowed 
Steady live-in partner 
 
Employment status: 
Unemployed 
Self-employed/own business  
Permanently employed 
Seasonal employment  
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Educational level: 
No schooling 
Primary level 
Secondary level 
Tertiary level 
 
Where do you live? __________________________________________ 
With whom do you live? 
With husband/wife 
With partner 
With family 
With friends 
Alone  
 
How many people live in the house? ______________ 
Do you take alcohol? ______________ 
Do you smoke? ______________________ 
When did you know you had HIV? _____________________ 
When did you start the HIV treatment? ____________________ 
How did you get to know about HIV and the treatment for HIV - HAART? 
From health workers 
From family 
From friends 
From the media 
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From the church 
Other  
 
How were you enrolled in this clinic? 
From the ANC 
From the TB programme 
From NewStart/other NGO 
From the wards/by health worker 
Self – referral  
 
At what time do you take your treatment? ______________________________________ 
For how long will you take the treatment? 
___________________________________________________________________________
___________________________________________________________________________ 
What helps you most to remember to take treatment? 
___________________________________________________________________________
___________________________________________________________________________ 
Are there times when sometimes you miss a dose or forget to take a dose, or do not fell like 
taking the medication? ________________________________ 
During the last one month, how often did you happen to miss your treatment? 
___________________________________________________________________________ 
If you miss your treatment, what do you do? 
___________________________________________________________________________
What is most challenging in taking the treatment? 
___________________________________________________________________________
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How has being on treatment influenced your life? 
___________________________________________________________________________ 
 
How does the treatment work? 
It cures HIV 
It kills the HIV 
It reduces the HIV 
It makes my body strong 
Don’t know 
Other (please specify) ________________________________________________ 
 
What would happen to you or the HIV virus if you did not take the medicines regularly? 
Nothing 
I would get sick 
The HIV would get worse 
The HIV would become resistant to the medicines 
I would get better 
Don’t know 
Other (please specify) ________________________________________________ 
 
How has being on treatment affected your daily life or family? 
___________________________________________________________________________
___________________________________________________________________________ 
Have you ever received any counselling about HIV or the HIV treatment? 
___________________________________________________________________________ 
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How often have you received counselling? 
___________________________________________________________________________ 
What have you learned from the counselling and how has it helped you? 
___________________________________________________________________________
___________________________________________________________________________ 
Who supports you most about taking your medicines? 
___________________________________________________________________________ 
What sort of support does he/she give you? 
___________________________________________________________________________
___________________________________________________________________________ 
 
Do you know of any support groups in your area? __________________________________ 
Which ones? ________________________________________________________________ 
___________________________________________________________________________
___________________________________________________________________________ 
 
How did you get to know about the support groups? 
From the health worker 
From family member or friend 
From the media (radio, TV, newspapers) 
From the church 
Other (please specify) _________________________________________________ 
 
Are you a member of a support group? __________________________________ 
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If yes, what activities or support does the group give? 
___________________________________________________________________________
___________________________________________________________________________ 
If not, why not? 
Do not know of any support group 
Do not know how to join one 
Don’t want to be identified with a HIV-related group 
Just don’t want to join any 
Other (please specify) ___________________________________________________ 
 
What further support do you think you would need? _________________________________ 
___________________________________________________________________________
___________________________________________________________________________ 
 
How have you benefited from being on treatment? 
No benefit 
I’m cured of HIV 
I don’t get sick often 
I have gained weight 
I have gone back to work 
Now that you are on treatment, do find easier or difficult to talk about HIV? 
___________________________________________________________________________
___________________________________________________________________________ 
In your family, how many people have you told your HIV status? 
___________________________________________________________________________ 
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Among your friends and workmates, how many people have you told your HIV status? 
___________________________________________________________________________ 
What are the challenges you have faced since knowing your positive HIV status? 
___________________________________________________________________________
___________________________________________________________________________ 
How do you think the availability of treatment has influenced people’s attitude towards HIV? 
___________________________________________________________________________
___________________________________________________________________________ 
What challenges do you face in coming to the clinic for your treatment? 
___________________________________________________________________________
___________________________________________________________________________ 
How do you find the service offered at the clinic? 
___________________________________________________________________________
___________________________________________________________________________ 
Does the service at the clinic affect your motivation for the treatment? 
___________________________________________________________________________
___________________________________________________________________________ 
What would you like to see changed or improved in the clinic services? 
___________________________________________________________________________
___________________________________________________________________________ 
What message do you have for the clinic staff, the government or the Namibian people? 
___________________________________________________________________________
___________________________________________________________________________ 
Thank you very much for your time. 
God bless you and keep on adhering to you HAART medications. 
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Appendix 2 
 
UNIVERSITY OF THE WESTERN CAPE 
             School of Public Health 
               Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
PARTICIPANT INFORMATION SHEET 
 
Request for your participation in a research 
 
I am Wambui Njuguna, a student at the School Of Public Health (SOPH), University of 
Western Cape (UWC). I would like to request for your participation in a research I am 
conducting. The research is for a Mini-Thesis – which is part of the requirement for a Masters 
degree in Public Health (MPH). 
 
Following is information about the research. 
 
Title of research 
Adherence to HAART among patients in the Keetmanshoop ART Programme in Namibia  
 
Description of the research 
The research seeks to find out about adherence to HIV treatment and what factors are 
influencing adherence here in Keetmanshoop. The research has been approved by the 
University of Western Cape and the Ministry of Health and Social Services, Namibia. The 
study will include a review of your clinical record and an interview with you through a 
questionnaire. I will collect information from your clinical records. I will also ask you 
questions about your HIV treatment and how you are coping with the treatment. All this 
information will only be used for this research. 
 
Participation 
Your participation in the research is voluntary, i.e. of your own free will. You are also free to 
withdraw from the research at any time should you wish to do so. If there is any detail or 
question that is not clear, please ask so that I can clarify further. If there is a question you do 
not feel comfortable answering, you do not have to answer it.  
 
There is no expected benefit or harm to you from the research. It is hoped that the research 
will impact positively on the services you and others receive from this program. 
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Anonymity and Confidentiality 
Your identity will be kept anonymous. Your name will not appear on the questionnaire and 
the information you provide will not be linked back to you in any way. The consent form that 
you sign will be kept separately from the questionnaires. All the documents pertaining to the 
study will be kept safely until completion the study. Once data analysis is done and the study 
report written, the documents will be destroyed. 
 
Uses of the research 
The research will be used for a mini-thesis, to obtain a Masters degree in Public Health at the 
University of the Western Cape. 
A report of the research will also be made available to the Ministry of Health and Social 
Services, Namibia, through the Keetmanshoop Health District Coordinating Committee.  
 
Informed Consent 
If you decide to take part in the research, I will ask you to sign the attached consent form as 
prove that you have agreed to participate in the research. 
 
Contact details 
Thank you for agreeing to take part in the research. 
I am accountable to Dr Brian Van Wyk, my supervisor for the Mini-Thesis. 
 
Should you have any further queries, feel free to contact me or my supervisor. 
The contact details are: 
 
Wambui Njuguna 
Student number: 2655201 
Tel: 264813643829 
Email: njuguwa@yahoo.com 
 
Dr Brian Van Wyk 
School of Public Health 
University of Western Cape 
Tel: 27219592173 
Email:  bvanwyk@uwc.ac.za 
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Appendix 3 
 
                                      UNIVERSITY OF THE WESTERN CAPE 
                                             SCHOOL OF PUBLIC HEALTH 
         Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
   Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
RECORD OF INFORMED CONSENT TO CONDUCT AN INTERVIEW 
 
Researcher: Wambui Njuguna  
UWC Student number: 2655201 
Tel: +264813643829 
E-mail: njuguwa@yahoo.com 
Place: Keetmanshoop state hospital 
 
Interviewer Agreement 
I agree to conduct a research on the participant whose signature appears below. 
I undertake to keep the participant’s identity and the contents of the research interview 
confidential. I will use the information gathered for the purposes of a mini-thesis. Any change 
from this agreement will be renegotiated with the participant. 
 
Interviewee Agreement 
I have read the participant information sheet / the contents of the participant information 
sheet have been explained to me.  
I fully understand that I am taking part in a research and I am participating voluntarily. The 
research will be used for a Mini-Thesis and includes collecting information from my clinical 
records and information from me about my HIV treatment. I have been assured that this 
information will be confidential. 
I hereby give consent to participate in the research. 
 
Signed by Interviewee: 
 
 
Signed by interviewer: 
 
 
Date: 
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REPUBLIC OF NAMIBIA 
 
 
 
 
Ministry of Health and Social Services 
Private Bag 13198     Ministerial Building                   Tel: (061) 2032562 
Windhoek                                    Harvey Street                                  Fax: (061) 272286 
Namibia     Windhoek                                   E-mail:hilmanangombe@yahoo.com 
Enquiries: Ms. H. Nangombe Ref.: 17/3/3/AP                                        Date: 16 March 2009 
 
OFFICE OF THE PERMANENT SECRETARY 
 
Dr. Wambui Njuguna  
P.O. Box 1875  
KEETMANSHOOP  
 
Dear Dr. Njuguna, 
 
RE: ADHERENCE TO HIGHLY ACTIVE ANIT -RETROVIRAL TREATMENT AMONG  
PATIENTS IN THE KEETMANSHOOP ANTI-RETROVIRAL THERAPY PROGRAMME IN  
NAMIBIA. 
 
1. Reference is made to your application to conduct the above-mentioned study. 
 
2. The proposal has been evaluated and found to have merit. 
 
3. Kindly be informed that approval has been granted under the following conditions: 
  
3.1  The data collected is only to be used for your academic purpose;  
3.2  A quarterly progress report is to be submitted to the Ministry's Research Unit;  
3.3  Preliminary findings are to be submitted to the Ministry before the final report;  
3.4  Final report to be submitted upon completion of the study;  
 3.5  Separate permission to be sought from the Ministry for the publication of the findings.  
 
 
 
 
 
 
 
 
 
